Axillary Reverse Mapping Improves Quality of Life by Significantly Reducing Clinically Relevant Lymphedema After Axillary Lymph Node Dissection in Older Women with Breast Cancer.

Breast cancer-related lymphedema (BCRL) is one of the most debilitating long-term morbidities after axillary lymph node dissection (ALND), severely impairing quality of life through reduced mobility, independence, and chronic burden, especially in older women. Axillary reverse mapping (ARM) aims to preserve upper extremity lymphatics while maintaining oncologic safety. Evidence in older adult populations with long-term follow-up remains limited. This retrospective cohort study included 138 female patients (median age 72.5 years) undergoing ALND for invasive breast cancer between January 2018 and January 2024. Patients were divided into ARM (n = 72) and non-ARM (n = 66) groups. BCRL was graded 0-3 according to adapted International Society of Lymphology (ISL) criteria (2013 consensus document). Assessments were performed preoperatively and at 3, 6, 12, 24, 36, 48, and 60 months using blinded circumference measurements and bioimpedance spectroscopy. Baseline characteristics were comparable. Mean follow-up was 46.5 ± 8.8 months. Clinically relevant BCRL (Grades 2-3) was dramatically lower in the ARM group (18.1% vs. 60.6%, < 0.0001), while subclinical changes (Grade 1) were similar (31.9% vs. 27.3%, = 0.55). Kaplan-Meier analysis showed significantly better clinically relevant lymphedema-free survival with ARM (log-rank = 0.00019), with curve separation after 30-40 months-indicating a sustained long-term benefit for quality of life in this frail population. Recurrence rates were comparable (8.3% vs. 10.6%, = 0.776). Multivariable Cox regression confirmed ARM as an independent protective factor (adjusted HR 0.22, 95% CI 0.11-0.44, < 0.0001). In older women with breast cancer, ARM significantly reduces clinically relevant lymphedema-a major determinant of long-term quality of life-without compromising oncologic safety. These findings support the routine consideration of ARM during ALND to preserve upper-extremity function, mobility, and independence in this vulnerable population, thereby balancing aggressive oncologic treatment with enhanced long-term quality of life and reduced treatment-related morbidity.